Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-007-4 | CAS number: 10016-20-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline Study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD guidelines for Testing of Chemicals, no. 401
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Cyclohexapentylose
- EC Number:
- 233-007-4
- EC Name:
- Cyclohexapentylose
- Cas Number:
- 10016-20-3
- Molecular formula:
- C36H60O30
- IUPAC Name:
- (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31R,32R,33R,34R,35R,36R,37R,38R,39R,40R,41R,42R)-5,10,15,20,25,30-Hexakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29-dodecaoxahe ptacyclo[26.2.2.23,6.28,11.213,16.218,21.223,26]dotetracontane-31,32,33,34,35,36,37,38,39,40,41,42-dodecol
- Details on test material:
- designation: .alpha.-cyclodextrin
batch no.: V887
appeareance: white powder
Cas. Reg. no.: 18016-20-3
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- Swiss
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Young male and female Swiss-outbred mice (Crl: CD) were obtained from a colony, maintained under SPF conditions at the Breeding Centre for Laboratory Animals "Charles River Wiga GmbH", Sulzfeld, F.R. Germany. Upon arrival the mice were checked for signs of ill health and anomalies. The mice were kept under the environmental conditions of the Institute's animal house for an acclimatization period prior to the test. Within each group the mice were individually identified by one of five different V-shaped earmarks.
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- physiological saline
- Doses:
- 500, 750, 1000 or 2500 mg substance per kg body weight
- No. of animals per sex per dose:
- 2500 mg : 2 animals / sex
1000 mg: 1 animal / sex
750 mg: 5 animals / sex
500: 1/ sex (pre experiment) and 4/ sex - Control animals:
- not specified
- Details on study design:
- The substance was given intravenously by tail vena punction as a solution in sterile saline to male and female mice, in single doses.
The mice were observed frequently for signs of intoxication, during the first 4 hours after treatment and thereafter, at least once daily throughout an observation period of 14 days. The individual body weights of the mice were recorded on day 0, 3, 7 and 14. At the end of the observation period, the mice were killed for macroscopic examination.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- other: intravenous LD50
- Effect level:
- > 750 - < 1 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All animals of the two highest dose groups (2500 and 1000 mg/kg), one male and one female of the 750 mg/kg group and three females of
the 500 mg/kg group died within a few days after treatment. - Clinical signs:
- Dose-related signs of intoxication were observed within one hour to a few days after treatment in all dose groups, such as sluggishness and piloerection. Survivors generally showed decreased growth rate however, the animals recovered and looked quite healthy again at the end of the observatio period.
- Body weight:
- no data available
- Gross pathology:
- At autopsy a dark spleen was observed in all animals of the highest dose group of 2500 mg/kg and moreover, in males of the same dose group a yellowish mucous in the abdomen was observed.
- Other findings:
- See Gross pathology. Marcroscopic examination of all other animals that were found dead and of survivors at the end of the observation period did not reveal treatment-related gross alterations.
Applicant's summary and conclusion
- Conclusions:
- From the data presented it is concluded that the intravenous LD50 of .alpha.-cyclodextrin is between 750 and 1000 mg/kg body weight.
- Executive summary:
The acute intravenous toxicity of .alpha.-cyclodextrin was determined in mice.
The test substance was given by intravenous injection as a solution in sterile saline to male and female mice in single doses of 500, 750, 1000 or 2500 mg substance per kg body weight.
The main test consisted of three experiments.
Dose-related signs of intoxication were observed within one hour to a few days after treatment in all dose groups, such as sluggishness and piloerection. All animals of the two highest dose groups (2500 and 1000 mg/kg), one male and one female of the 750 mg/kg group and three females of the 500 mg/kg group died within a few days after treatment. Survivors generally showed decreased growth rate however, the animals recovered and looked quite healthy again at the end of the observation period. At autopsy a dark spleen was observed in all animals of the highest dose group of 2500 mg/kg and moreover, in males of the same dose group a yellowish mucous in the abdomen was observed. Marcroscopic examination of all other animals that were found dead and of survivors at the end of the observation period did not reveal treatment-related gross alterations.
From the data presented it is concluded that the intravenous LD50 of .alpha.-cyclodextrin can be expected between 750 and 1000 mg/kg body weight.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.